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Abstract
Objectives: This study aimed to determine longterm outcomes and factors associated with increased
survival after photodynamic therapy (PDT) compared with endoscopic biliary drainage alone in patients
presenting with advanced hilar cholangiocarcinoma (CC).
Methods: A retrospective analysis of the institutional database identifying all patients who presented
with a diagnosis of hilar CC between December 1999 and January 2011 was conducted.
Results: Of the 232 patients identified, 72 (31%) were treated with PDT (Group A) and 71 (31%) were
treated with endoscopic biliary drainage alone (Group B). Median survival was 9.8 months [95% confi-
dence interval (CI) 7.42–12.25] in Group A and 7.3 months (95% CI 4.79–9.88) in Group B (P = 0.029). On
multivariate analysis, biliary drainage without PDT (P = 0.025) and higher T-stage (P = 0.002) were
significant predictors of shorter survival in all patients. In a subgroup analysis of patients in the PDT group,
lower pre-PDT bilirubin level (P = 0.005), multiple PDT treatments (P = 0.044) and shortened time to
treatment after diagnosis (P = 0.013) were significant predictors of improved survival. Median metal stent
patency was longer in Group A than in Group B (215 days vs. 181 days; P = 0.018).
Conclusions: Photodynamic therapy with stenting resulted in longer survival than stenting alone. Early
PDT after diagnosis and multiple PDT treatments were shown to have survival benefits. Metal stent
patency was longer in patients receiving PDT. Higher T-stage appears to be a predictor of early mortality
in advanced bile duct cancer treated with PDT.
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Introduction
Hilar cholangiocarcinoma (CC) is an uncommon neoplasm
arising from the biliary confluence or the right or left hepatic
ducts. The location of CC at the upper hepatoduodenal ligament,
its extension into the liver and its proximity to major vascular
structures render it difficult to evaluate before surgery and at
laparotomy.1
Longterm control of biliary carcinomas can only be obtained by
potentially curative surgery (i.e. the removal of all apparent
tumours). However, because characteristic early symptoms are
lacking, the disease is often at an advanced stage when a definitive
diagnosis is established.2 As a result, a large proportion of patients
are beyond the scope of curative treatment on diagnosis and can be
given only palliative management. In unresectable CC, usually the
only therapeutic strategy is improvement of cholestasis by endo-
scopic or percutaneous drainage or a biliary bypass.3,4 Although
metal stent insertion improves occlusion rates and reduces the
number of therapeutic interventions, it does not improve median
survival time.5 Attempts to affect tumour growth have been made
with radiotherapy or chemotherapy.However, these therapies have
not been demonstrated to prolong survival significantly.6,7
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A treatment modality for local ablation of the primary tumour
might improve the outcomes of curative as well as palliative thera-
pies. Recently, there have been several promising reports of the
outcomes of photodynamic therapy (PDT) as an advanced pallia-
tive strategy for CC, which have noted significant improvements
in quality of life and survival after PDT and stenting.8–10 However,
the longterm outcome of PDT has not been determined. The aim
of this study was to examine the longterm outcome and factors
associated with increased survival after PDT compared with those
after endoscopic biliary drainage alone in advanced hilar CC.
Materials and methods
Patients
A total of 232 patients with hilar CC treated between December
1999 and January 2011 were evaluated. Of these, 89 patients were
excluded for reasonsof surgery (n=38),palliative chemotherapyor
radiotherapy (n = 30), a Karnofsky performance status11 of <60
(n = 5), percutaneous biliary drainage only (n = 11), loss from
follow-up (n = 4), and sudden death during diagnostic workup
(n = 1). Thus, data for 143 patients were available for further
analysis. Of these patients, 72 (31%) were treated with PDT in
addition to biliary stenting without chemoradiation (Group A)
and 71 (31%) were treated with endoscopic stenting only (Group
B) (Fig. 1). Patients were allocated to one of these treatment
strategies based on their requirements after they had been
informed of the efficacy, side-effects and cost of PDT. Clinical,
laboratory, radiological, endoscopic and histopathological data
were collected prospectively and analysed retrospectively. All
patients included in this study were believed to be unresectable by
accepted criteria.12,13 The local institutional review board approved
this retrospective study.
Patients with unresectable hilar CC were offered PDT as a
palliative modality if they consented to PDT with percutaneous
transhepatic cholangioscopy (PTCS) or endoscopic retrograde
cholangiopancreatography (ERCP). Based on the Bismuth–
Corlette classification system,14 patients were eligible if they dem-
onstrated type IV lesions or advanced type III lesions containing
T3 tumours. Patients with other type II or III tumours in whom
surgery was contraindicated because of metastases, age >80 years
or the presence of other comorbid conditions were also eligible.
All patients were required to show a Karnofsky status of >60. All
tumours were staged using the American Joint Committee on
Cancer staging criteria (7th edition) for perihilar bile duct can-
cer.15 All patients underwent a standard pretreatment evaluation
that included thin-section, contrast-enhanced, multiphase spiral
computed tomography (CT) and/or magnetic resonance imaging
(MRI) of the abdomen. Resectability was defined according to the
criteria of Vauthey and Blumgart.16
Photodynamic therapy
Photodynamic therapy was administered using previously
described methods.17,18 Briefly, patients received porfimer sodium
(Photofrin II®; Axcan Pharma, Inc., Mont-Saint-Hilaire, QC,
Canada) i.v. at a dose of 2 mg/kg at 48 h before endoscopic (ERCP)
or percutaneous (PTCS) photoradiation. For light distribution,
flexible cylindrical diffuser probes (BioLitec Pharma Ltd, Stirling,
UK) mounted on 400-mm quartz fibres with an active distal tip
length of 2 cmwere used. The light source was a diode laser system
(Ceralas PDT 633; CeramOptec GmbH, Bonn, Germany) with a
maximum power output of 2 W and a wavelength of 633 3 nm.
Thepower emittedby thediffuser tipwas calibrated to400 mW/cm
before PDT was administered using an integrating sphere power
meter. The mean irradiation time was 452 s (range: 400–600 s),
using a power density of 300–400 mW/cm and an energy dose of
180–200 J/cm (of diffuser length). To perform the percutaneous
PDTprocedure, a guidewirewas first inserted through the stricture
into the common bile duct. A 6-Fr guiding catheter was then
inserted along the guidewire, permitting the guidewire to be
removed. A diffuser fibre was then inserted into the guiding
catheter and the stricture site was irradiated from the distal to
the proximal region under cholangioscopy and fluoroscopy.
Photodynamic therapy with PTCS was usually administered in
more advanced Bismuth type III lesions. To perform PDT with
ERCP, the preloaded catheter (catheter and PDT fibre) was
advanced across the bile duct tumour using a 0.035-inch guide-
wire. The tip of the catheter contained a metal marker and was cut
just below this marker to allow the fibre to pass. Tumour segments
were treated sequentially in aproximal-to-distal fashion.AfterPDT
was performed, 10-Fr plastic biliary stents were inserted to ensure
Included
n = 178
Group A Group B
Analysed (n = 72) Analysed (n = 71)
Lost from follow-up (n = 1)
Palliative chemotherapy
(n = 8)
Lost from follow-up (n = 3)
Palliative chemotherapy (n = 22)
Sudden death
    during diagnostic workup (n = 1)
PDT with stenting
n = 81
Endoscopic stenting only
n = 97
Patients with hilar cholangiocarcinoma (n = 232)
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Surgery (38)
Poor performance status (5)
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Figure 1 Flow chart showing participants included in and excluded
from the current study. PTBD, percutaneous transhepatic biliary
drainage; PDT, photodynamic therapy
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adequate decompression and bile drainage.Photodynamic therapy
with ERCPwas usually performed in cases of Bismuth type II, III or
IV lesions and in patients aged >80 years.
Follow-up
Patients were followed up at 3-month intervals and were offered
additional treatment with PDT, provided they were able to toler-
ate it and were willing to continue further treatment. Tumour
response was assessed every 3 months with tumour markers [car-
bohydrate antigen 19-9 (CA19-9)] and imaging studies (ERCP,
PTCS, MRI, chest radiography). Photodynamic therapy was
repeated whenever follow-up biopsies were tumour-positive or
when tumour progression was evident, based on ERCP, PTCS
or MRI. As a practical rule, 10-Fr plastic endoprostheses were
exchanged every 3–4 months to avoid occlusion and bacterial
cholangitis. Enrolled patients were followed until death. The indi-
cations for metal stents were: age >80 years; refusal of additional
PDT because of its high cost; referral from a distant location, and
change to poor performance status during follow-up. Metal stent
patency represented the time interval between stent insertion and
replacement. If the patient died with a patent stent, the time
interval was recorded as censored data. Successful drainage after
technically successful stenting was defined as a >50% decrease in
bilirubin level within 7 days of stenting.19
Statistical analysis
Statistical analyses were performed using spssVersion 13.0 (SPSS,
Inc., Chicago, IL, USA). Numerical data were presented as
medians with ranges. Intergroup comparisons were performed
using the Mann–Whitney U-test. Estimates of probabilities of
survival for the follow-up study and cumulative stent patency
were calculated using the Kaplan–Meier method with the log-rank
test. Data were summarized as medians with 95% confidence
intervals (CIs). For survival rates, all deaths related to CC and
procedures were included, but deaths unrelated to CC were
treated as censored. All data were analysed using an intention-to-
treat analysis. Intention-to-treat survival was calculated from the
day of treatment until death or the date of the last follow-up visit.
Cox regression was used to determine independent predictors
of outcome, using survival as the dependent variable and signifi-
cant factors (P < 0.15) determined by univariate analysis. P-values
of 0.05 were deemed to indicate statistical significance.
Results
Baseline clinical and demographic profiles in the two treatment
groups were similar, except in patients with Bismuth type IV
lesions (Table 1). Group A included more patients with Bismuth
type IV lesions than Group B (39/72 vs. 26/71; P = 0.036). There
was no significant difference in age, gender, pre-procedure biliru-
bin level, CA19-9 level or tumour stage between the groups.Of the
72 patients in Group A, the PDT fibre was placed after the bile
duct was accessed via PTCS in 59 (82%) patients and endoscopi-
cally (via ERCP) in 13 (18%) patients. The diagnosis was con-
firmed by histological analyses in 57 (79%) patients in Group A
and 38 (54%) in Group B. Histological confirmation of malig-
nancy in Group A was obtained by brush cytology in six ERCP
patients and by intraductal biopsy examination in 51 PTCS
patients. In Group B, histological confirmation was obtained by
brush cytology in 25 ERCP patients, by intraductal biopsy in six
direct cholangioscopy (mother–babyscope technique) patients,
and by percutaneous ultrasonography-guided biopsy in seven
patients. Patients received a total of 99 PDT treatments (median =
1; range: 1–4). Overall, 51 (71%), 16 (22%), four (6%) and one
(1%) patient received one, two, three or four PDT treatments,
respectively.
Successful drainage was achieved in 92% and 83% of patients
in Groups A and B, respectively. Median bilirubin levels before
the start of therapy in Groups A and B were 11.3 mg/dl (range:
0.9–27.6 mg/dl) and 10.5 mg/dl (range: 0.8–32.9 mg/dl), respec-
tively. At 7 days, median bilirubin levels in Groups A and B had
decreased to 2.8 mg/dl (range: 0.4–12.6 mg/dl) and 3.6 mg/dl
(range: 0.3–11.4 mg/dl), respectively.No significant difference was
observed in the degree of decrease in bilirubin level between the
two groups (P = 0.131).
Eighteen patients in Group A (25%) and 15 patients in Group
B (21%) underwent biliary drainage with plastic stent insertion
followed by the placement of a self-expanding metal stent (Group
A: plastic stent before metal stent, n = 13, percutaneous transhe-
patic biliary drainage before metal stent, n = 5; Group B: plastic
stent before metal stent, n = 15). In a subgroup analysis of patients
in whom a metal stent was inserted, duration of stent patency was
longer in Group A than in Group B (Fig. 2). The median stent
patency was 215 days (range: 72–570 days) in Group A and 181
days (range: 70–209 days) in Group B (P = 0.018).
Survival
The median follow-up periods from diagnosis to death in Groups
A and B were 11.3 months (range: 2.4–44.3 months) and 9.1
months (range: 0.9–34.6 months), respectively (P = 0.038).
Kaplan–Meier survival analysis showed a significantly longer sur-
vival time in Group A (PDT) compared with the endoprostheses
group (Fig. 3). Median survival was 9.8 months (95% CI
7.42–12.25) in Group A and 7.3 months (95% CI 4.79–9.88) in
Group B (P = 0.029). The 1-, 2- and 3-year survival rates were
39.4%, 13.9% and 4.1% in Group A and 26.6%, 9.4% and 0% in
Group B, respectively.
Kaplan–Meier survival curves according to tumour stage are
illustrated in Fig. 4. One-year survival was 75.0% in stage II,
36.3% in stage III (IIIa/IIIb) and 24.2% in stage IV (IVa/IVb)
disease. Median survival was 14.5 months (95% CI 12.89–16.17)
in stage II, 9.4 months (95% CI 7.40–11.34) in stage III and 7.6
months (95% CI 6.13–9.13) in stage IV disease.
At the end of the observation period, all patients in Group A
had died and only one patient in Group B remained alive. Causes
of death in Group A patients were tumour progression (61%,
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Table 1 Characteristics of patients in Groups A (photodynamic therapy with stenting) and B (stenting only)
Group A (n = 72) Group B (n = 71)
Age, years, median (range) 62.5 (36–89) 67 (42–85)
Male sex, n (%) 46 (64) 49 (69)
AJCC stagea, n (%)
II 8 (11) 5 (7)
IIIa/IIIb 9 (13)/21 (29) 9 (13)/20 (28)
IVa/IVb 20 (28)/14 (19) 17 (24)/20 (28)
Bismuth type, n (%)
II 6 (8) 16 (23)
IIIa/IIIb 9 (13)/18 (25) 20 (28)/9 (13)
IVa/IVb 25 (35)/14 (19) 6 (8)/20 (28)
Liver metastasis, n (%) 10 (14) 12 (17)
CA19-9, U/ml, median (range) 711.6 (0.9–4800) 925.5 (1.36–4800)
Bilirubin, mg/dl, median (range)
Pretreatment 9.9 (0.6–34.8) 11.6 (0.5–32.9)
Post-treatment 1.8 (0.3–14.3) 3.1 (0.3–29.8)
Pre-PDT albumin, g/dl, median (range) 3.5 (2.0–4.5) 3.4 (2.0–4.6)
PDT method, n (%)
PTCS 59 (82)
ERCP 13 (18)
Type of stent, n (%)
Plastic 54 (75) 56 (79)
Metal 18 (25) 15 (21)
aAmerican Joint Committee on Cancer, 7th edition.
CA19-9, carbohydrate antigen 19-9; PDT, photodynamic therapy; PTCS, percutaneous cholangioscopy; ERCP, endoscopic retrograde
cholangiopancreatography.
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Figure 2 Kaplan–Meier estimation of metal stent patency rates in Groups A and B. Median stent patency was longer in Group A (215 days)
than in Group B (181 days) (P = 0.018). PDT, photodynamic therapy; ERBD, endoscopic retrograde biliary drainage
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Figure 3 Kaplan–Meier curves showing overall survival in Group A [photodynamic therapy (PDT) with stenting] and Group B (stenting only).
Median survival was 9.8 months [95% confidence interval (CI) 7.42–12.25] in Group A and 7.3 months (95% CI 4.79–9.88) in Group B
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n = 44), acute liver failure (22%, n = 16), biliary sepsis (11%, n =
8), and non-CC-related causes (6%; variceal bleeding n = 1, lung
cancer n = 1, heart disease n = 2). Causes of death in Group B were
tumour progression (66%, n = 46), acute liver failure (11%, n = 8),
biliary sepsis (20%, n = 14) and variceal bleeding (3%, n = 2).
Chronic cholangitis led to secondary biliary cirrhosis and fatal
complications, such as variceal bleeding, in three patients without
tumour progression.
Prognostic factors analysis
Table 2 shows the results of univariate and multivariate analysis
of all variables associated with survival in all patients. Levels of
CA19-9 [hazard ratio (HR) = 1.47, 95% CI 1.003–2.613;
P = 0.047] and bilirubin (HR = 1.65, 95% CI 1.139–2.401;
P = 0.005) at diagnosis, T-stage (HR = 1.80, 95% CI 1.205–2.679;
P = 0.004) and treatment group (HR = 1.46, 95% CI 1.037–
2.046; P = 0.029) were statistically significant predictors of
survival on univariate analysis. Findings regarding tumour stage
showed that survival after diagnosis was longer in stage II
patients than in stage IV patients (median survival: 14.5 months
vs. 7.6 months; P = 0.036), but did not significantly differ
between stage II and III patients (median survival: 14.5 months
vs. 9.4 months, respectively; P = 0.166). Factors including lower
serum albumin level before treatment, gender, Bismuth type,
PDT method (PTCS vs. ERCP) and lymph node involvement did
not significantly affect survival according to univariate analyses.
Multivariate analysis using Cox regression in all patients showed
that lack of biliary drainage and higher T-stage were significant
predictors of shorter survival in advanced hilar CC. A subgroup
analysis of Group A (PDT group) data (Table 3) showed that
increased time to treatment after diagnosis (Fig. 5), a higher
pretreatment bilirubin level and a single PDT treatment were
statistically significant predictors of shorter survival after PDT.
Adverse events
It is not possible to differentiate clinically between cholangitis
induced by tumour progression and that induced by the endo-
scopic procedure; thus the incidence of cholangitis was not com-
pared between the two groups. In Group A, hyperpigmentation of
the skin occurred in 10 patients (14%) and cutaneous complica-
tions, including erythema or facial oedema, were seen in one
patient, but skin abnormalities improved with conservative treat-
ment. Biliary leakage occurred in one of 99 PDT treatments.
Sepsis occurred in one patient after the second PDT treatment. A
liver abscess occurred in one patient after an initial PDT treatment
with PTCS; further PDT was stopped and supportive care was
given. With respect to complications related to the PTCS tube,
tube breakage, bile leakage from the tube insertion site and pre-
mature exchange of the PTCS tube as a result of early tube occlu-
sion occurred in one, two and three patients, respectively.
Table 2 Results of univariate and multivariate analyses of all prognostic factors associated with survival in all patients
Variable Univariate (Kaplan–Meier and log-rank test) Multivariate (Cox proportional hazards model)a
Cases Median survival, months P-value HR 95% CI P-value
Age, years
<65 vs. 65 68:75 9.2:8.5 0.331
Gender
Male vs. female 95:48 9.6:8.6 0.359
CA19-9, U/ml
<100 vs. 100 38:102 13.0:8.4 0.047 1.35 0.910–1.995 0.136
Serum albumin, g/dl
<3.5 vs. 3.5 73:70 8.2:9.6 0.198
Pre-PDT bilirubin, mg/dl
<3.0 vs. 3.0 43:100 11.6:8.1 0.005 1.26 0.852–1.881 0.244
Tumour stageb
T2 vs. T3, T4 37:106 11.6:8.2 0.004 1.93 1.261–2.937 0.002
Lymph node involvement
Yes vs. No 95:48 9.5:8.6 0.943
Bismuth type
II, III vs. IV 78:65 9.1:8.6 0.649
Treatment group
PDT vs. ERBD 72:71 9.8:7.2 0.029 1.53 1.056–2.221 0.025
aFactors were included in multivariate analysis if P < 0.05 in univariate analysis.
bAmerican Joint Committee on Cancer, 7th edition.
HR, hazard ratio; 95% CI, 95% confidence interval; CA19-9, carbohydrate antigen 19-9; PDT, photodynamic therapy; ERBD, endoscopic retrograde
biliary drainage.
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In Group B, stent migration subsequent to cholangitis occurred
in 11 patients (16%; one metal stent and 10 plastic stents). Two
patients developed an infected biloma with prolonged cholangitis
after endoprostheses and weremanaged with antibiotic treatment.
Discussion
Complete surgical resection remains the foundation of therapy
with curative intent in patients with extrahepatic CC, but because
of its anatomic location and natural history, the disease is locally
advanced in most patients at the time of diagnosis. Patients with
unresectable CC have few therapeutic options other than pallia-
tive biliary stenting. Although metal stent insertion improves
occlusion rates and reduces the number of therapeutic inter-
ventions, it does not extend median survival.5 Chemotherapy is
widely regarded as ineffective for biliary tract cancer. A meta-
analysis of 2810 patients in 104 mostly small, non-randomized
studies reported a median response rate of 23% and a small sur-
vival advantage (1 month) in those undergoing chemotherapy,
particularly using gemcitabine and platinum-based regimens.20 A
treatment modality for local ablation of the primary tumour
might improve the outcomes of curative and palliative therapies.
Palliative brachytherapy with 192-iridium alone (35 Gy at a 1-cm
distance) did not prolong median survival time (4.3–5.0
months),21 but, when combined with external beam radiotherapy
(30 Gy), this treatment did result in median survival times of
10.0–10.5 months.22 Another modality for local tumour ablation
of CC is PDT. Even in patients with advanced disease, PDT has
been shown to improve survival, quality of life and performance
status, compared with biliary stenting, in uncontrolled8,23 and ran-
domized controlled trials.10,24 The overall median survival after
PDT in the current study was 9.8 months, which is similar to rates
in previous reports.8,25
A subgroup analysis in the PDT group showed a high pretreat-
ment bilirubin level to be strongly related to poor survival. Effec-
tive palliation is essential because biliary drainage and prevention
of cholestasis are crucial to prevent pruritus, cholangitis and
death. The approach to palliative decompression has evolved from
surgery and percutaneous to endoscopic management with the
aim of preventing cholestasis and improving mortality rates.
Table 3 Results of univariate and multivariate analyses of all prognostic factors associated with survival in patients receiving photodynamic
therapy
Variable Univariate (Kaplan–Meier and log-rank test) Multivariate (Cox proportional hazards model)a
Cases Median survival, months P-value HR 95% CI P-value
Age, years
<65 vs. 65 42:30 9.1:11.2 0.809
Gender
Male vs. female 46:26 11.7:9.1 0.621
CA19-9, U/ml
<100 vs. 100 22:49 12.2:9.1 0.760
Serum albumin, g/dl
<3.5 vs. 3.5 35:37 8.6:11.7 0.830
Pre-PDT bilirubin, mg/dl
<3.0 vs. 3.0 30:42 11.9:8.5 0.012 2.25 1.337–3.798 0.002
Tumour stageb
T2 vs. T3, T4 18:54 11.2:9.4 0.244
Lymph node involvement
Yes vs. No 46:26 9.8:9.3 0.518
Bismuth type
II, III vs. IV 33:39 10.4:9.2 0.977
PDT method
PTCS vs. ERCP 59:13 9.8:9.3 0.719
Time to PDT after
diagnosis, months
<3 vs. 3 54:18 11.9:9.1 0.034 2.11 1.173–3.795 0.013
Number of PDT treatments
1 vs. 2 51:21 8.7:12.2 0.048 1.79 1.044–3.083 0.034
aFactors were included in multivariate analysis if P < 0.05 in univariate analysis.
bAmerican Joint Committee on Cancer, 7th edition.
HR, hazard ratio; 95% CI, 95% confidence interval; CA19-9, carbohydrate antigen 19-9; PDT, photodynamic therapy; PTCS, percutaneous
cholangioscopy; ERBD, endoscopic retrograde biliary drainage.
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Unfortunately, the benefit of ERCP with stent placement is often
obviated by proximal tumour obstruction.26,27 To address this
issue, multiple studies have investigated the effects of combining
bile duct stent insertion with PDT.8,10,23 Photodynamic therapy
offers the possibility of ‘remodelling’ the tumoral mass,28 which
may enhance or prolong the decompressive effect.
T-stage was an independent predictor of survival on multivari-
ate analysis in all patients with hilar CC, although it was not
significant in subgroup analysis of the PDT group. Another study
demonstrated efficient selective tumour destruction of CC within
a superficial 4-mm layer.28 Therefore, PDT with haematoporphy-
rin derivatives [porfimer sodium (Photofrin II®; Axcan Pharma,
Inc.)] in localized hilar CC will not be potentially curative until
the procedure can be improved to exert selective tumour destruc-
tion for a wall thickness of 8–10 mm.
In a subgroup analysis of patients in whom metal stents were
inserted, the duration of stent patency was longer in GroupA than
in Group B. Median stent patency was 215 days in Group A and
181 days in Group B (P = 0.018). One of the main causes of the
obstruction of metal stents in bile duct cancer is tumour ingrowth
or overgrowth.29 In particular, the duration of metal stent patency
in hilar CC is shorter than in distal bile duct cancer.19,26 Thus, the
effect of PDT in destroying cancer and neovascular cells induced
the prolongation of stent patency. However, further randomized
studies are needed to confirm this.
Survival in patients who received multiple PDT treatments was
significantly longer than that in patients who underwent a single
PDT treatment in univariate analysis. The authors have previ-
ously examined the potential value of monthly follow-up evalu-
ations using intraductal ultrasonography (IDUS) to assess
response to PDT in hilar CC.17 Three months after PDT, the
mean thickness of the tumour mass had significantly decreased,
and the mean thickness of the tumour had increased at 4 months
after PDT.17 Based on these findings, it was recommended that
PDT in advanced hilar CC be repeated every 3 months.17
However, many of the patients in this study were referred from
distant places and were of poor economic status, which made it
difficult for them to return for subsequent treatments. A major
obstruction to repeated treatment was the high cost of PDT.
Thus, if the cost of PDT could be lowered, multiple sessions of
PDT would become possible and a subsequent improvement in
survival rates might be expected.
Extrabiliary spread, such that involving lymph nodes, vascular
invasion or encasement, and distant metastases, was not shown to
be a significant predictor of survival in this study. More than 50%
of the patients in this study demonstrated extrabiliary spread.
Time from diagnosis to treatment with PDT was a significant
factor not only in univariate analysis, but also in multivariate
analysis. Similar findings were reported in another study.30 The
negative effect of a prolonged time interval from diagnosis to
treatment on survival reflects a progressively increasing tumour
burden. This study indicated that for maximal survival benefit
with PDT, patients should be treated as soon as possible after a
diagnosis of unresectable CC is confirmed. Earlier treatment may
prevent a subsequent delay caused by biliary obstruction, as well
as loss of hepatic function.
This study was limited by the retrospective nature of its design.
However, the study population was derived from a larger cohort of
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Figure 5 Kaplan–Meier curves showing overall survival [from date of photodynamic therapy (PDT) to death or last follow-up evaluation].
Median survival was 11.9 months [95% confidence interval (CI) 6.09–17.64] in patients in whom the time from diagnosis to PDT was 3
months and 9.1 months (95% CI 7.88–10.32) in patients in whom the time from diagnosis to PDT was >3 months (P = 0.022)
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patients with CC and patients were followed until death. Median
survival in this cohort was comparable with that in other cohorts
reported in the literature. Additional PDT (i.e. local ablative
therapy) and systemic chemotherapy may create a synergistic
effect that improves survival and quality of life in advanced bile
duct cancer. Thus, further prospective randomized controlled
studies comparing outcomes of chemotherapy with PDT and che-
motherapy alone are required to confirm the role of PDT in
advanced bile duct cancer.
In summary, PDT with stenting resulted in longer survival than
stenting alone. Survival was also improved by the provision of
early PDT after diagnosis and multiple PDT treatments. Metal
stent patency was longer in patients receiving PDT. A higher
T-stage appears to be a predictor of early mortality in advanced
bile duct cancer treated with PDT.
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